CONCORDBIO Stock Overview
A biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Concord Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,600.95 |
| 52 Week High | ₹1,799.00 |
| 52 Week Low | ₹900.05 |
| Beta | 0 |
| 11 Month Change | 3.79% |
| 3 Month Change | -1.04% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 69.81% |
Recent News & Updates
Concord Biotech Limited (NSE:CONCORDBIO) Not Lagging Market On Growth Or Pricing
Jul 23
Is Concord Biotech (NSE:CONCORDBIO) Using Too Much Debt?
Feb 14Shareholder Returns
| CONCORDBIO | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.5% | 3.8% | 2.8% |
| 1Y | n/a | 51.0% | 47.6% |
Return vs Industry: Insufficient data to determine how CONCORDBIO performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CONCORDBIO performed against the Indian Market.
Price Volatility
| CONCORDBIO volatility | |
|---|---|
| CONCORDBIO Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: CONCORDBIO has not had significant price volatility in the past 3 months.
Volatility Over Time: CONCORDBIO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 1,377 | Sudhir Vaid | www.concordbiotech.com |
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications.
Concord Biotech Limited Fundamentals Summary
| CONCORDBIO fundamental statistics | |
|---|---|
| Market cap | ₹171.61b |
| Earnings (TTM) | ₹3.08b |
| Revenue (TTM) | ₹10.17b |
54.4x
P/E Ratio16.5x
P/S RatioIs CONCORDBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CONCORDBIO income statement (TTM) | |
|---|---|
| Revenue | ₹10.17b |
| Cost of Revenue | ₹2.45b |
| Gross Profit | ₹7.72b |
| Other Expenses | ₹4.64b |
| Earnings | ₹3.08b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 29.45 |
| Gross Margin | 75.93% |
| Net Profit Margin | 30.30% |
| Debt/Equity Ratio | 0.4% |
How did CONCORDBIO perform over the long term?
See historical performance and comparison